Neutral outlook for Sanofi — price forecast suggests continued sideways action

Traders Union
All News
Financial News
Sanofi slips 0.27% to $86.35 today

Highlights

Sanofi (SAN) trades at $86.35, above its MA-20 ($83.17) and MA-50 ($83.07) but below MA-200 ($91.14), indicating short- and medium-term bullishness with longer-term resistance.
Oscillators show mixed signals: RSI at 74.77 and CCI at 77.25 suggest near-overbought conditions, but momentum is weak with conflicting MACD, ADX, and Awesome Oscillator readings.
Sanofi's expected five-day price range is $85.15–$85.49 with less than 20% probability of a short-term increase, favoring sideways or weaker trading near $85–$86.

Mixed momentum and overbought signals as price faces resistance

The nearest dynamic support sits near the Ichimoku Kijun level at $81.60, while resistance is seen at the MA-50 or the next round number near $87. Momentum readings are mixed. D1 MACD signals ongoing upward momentum, while the weak D1 ADX suggests the move lacks strength. RSI at 74.77 and CCI at 77.25 flag near-overbought conditions, with Stoch RSI also elevated, while Bull/Bear Power is neutral, signaling no clear intraday dominance. The Awesome Oscillator does not support the current uptrend and instead adds to the divergence. Today's price has slipped 0.27% ($0.23 lower), opening with a minor gap down from $86.58 to $85.90. The current price sits mid-range between today's high ($86.71) and low ($85.90). Volatility is moderate, with intraday tone indicating slight pressure after the open, and oscillators overall provide conflicting signals versus price action.

Further weakness likely as bullish breakout odds diminish

For the next five trading days, the expected price range is $85.15 to $85.49, with the average near $85.32. The probability of a short-term price increase is very low (less than 20%), making further weakness more likely. In the baseline scenario, SAN trades sideways around $85–$86. A bullish scenario would see a breakout above $87, testing resistance closer to $91, while a bearish scenario would develop if support at $85.15 is lost, opening the way toward the lower $83–$84 area.

Viktoras Karapetjanc, Traders Union expert, sees Sanofi maintaining positive short- to medium-term momentum above key moving averages, although long-term resistance at $91.14 still contains price action. He notes that short-term technical indicators are sending mixed signals and momentum appears tentative, but with oscillators near overbought and volatility moderate, weakness could persist unless fresh catalysts emerge. In the coming days, Karapetjanc expects price action to consolidate near the $85–$86 range, with a bullish scenario requiring a convincing break above $87. "While the short-term pullback may continue, the constructive setup above dynamic support suggests any breakout above $87 could quickly attract renewed buy-side interest," he concludes.

Last time we reported that the FDA had accepted Sanofi's supplemental biologics license application for Tzield for expedited review, granting the possibility of fast-track approval in the US. Meanwhile, technical analysis signaled mixed technical signals as buyers lead despite weak trend strength in the near term.

Source of Data: SAN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.